Health
Phase 3 trials show AstraZeneca COVID vaccine has up to 90% efficacy – CIDRAP
The peer-reviewed data mirror unpublished results noted last month by the researchers, with up to 90% protection.
The first full peer-reviewed results of phase 3 trials of the COVID-19 vaccine developed by AstraZeneca and Oxford University show that it is safe and up to 90% effective in preventing infection, supporting regulatory submissions for emergency use.
The interim analysis, published today in The Lancet, identified no severe coronavirus disease or hospitalizations in pooled results from the 11,636 adults vaccinated in the United Kingdom and Brazil. Of the 11,636 adults, 131 (1.1%) had symptomatic COVID-19…
-
General16 hours agoInternal Revenue Service starts cutting 20,000 workers
-
General20 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening
-
Business17 hours ago$10,000 invested in ANZ shares 5 years ago is now worth…
-
Noosa News20 hours agoRates on hold; pressure builds for cuts in May